Ibalizumab-uiyk
Ibalizumab-uiyk (pronounced as i bal' iz ue mab) is a monoclonal antibody used for the treatment of HIV-1 infection in adults. It is marketed under the brand name Trogarzo.
Etymology
The name "Ibalizumab-uiyk" is derived from the International Union of Pure and Applied Chemistry (IUPAC) nomenclature for monoclonal antibodies. The "-mab" suffix indicates it is a monoclonal antibody, "-izu-" denotes it targets the immune system, and "-bal-" is a unique stem used for the drug.
Usage
Ibalizumab-uiyk is used in combination with other antiretroviral agents for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection, who are failing their current antiretroviral regimen.
Mechanism of Action
Ibalizumab-uiyk binds to the second extracellular domain of the CD4+ T cell receptor, preventing the viral entry and replication of HIV-1. It does not interfere with the normal function of CD4+ T cells.
Related Terms
See Also
External links
- Medical encyclopedia article on Ibalizumab-uiyk
- Wikipedia's article - Ibalizumab-uiyk
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski